Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $196.00 at Morgan Stanley

Neurocrine Biosciences (NASDAQ:NBIX) had its target price lifted by equities research analysts at Morgan Stanley from $193.00 to $196.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 17.60% from the stock’s current price.

A number of other equities analysts have also recently issued reports on NBIX. Stifel Nicolaus boosted their price objective on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday. Citigroup increased their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Needham & Company LLC lifted their target price on Neurocrine Biosciences from $200.00 to $204.00 and gave the stock a “buy” rating in a research report on Friday. Leerink Partners boosted their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Canaccord Genuity Group upped their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $199.36.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX traded down $18.83 during trading hours on Friday, hitting $166.67. 2,737,211 shares of the company’s stock traded hands, compared to its average volume of 1,191,972. The firm has a market capitalization of $16.76 billion, a P/E ratio of 25.68, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39. The business has a fifty day moving average price of $167.61 and a 200-day moving average price of $146.25. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the sale, the insider owned 54,729 shares in the company, valued at approximately $9,829,328.40. The trade was a 15.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the completion of the sale, the director directly owned 1,588 shares of the company’s stock, valued at $289,031.88. The trade was a 44.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 395,422 shares of company stock valued at $62,448,693 in the last ninety days. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. DJE Kapital AG bought a new position in Neurocrine Biosciences in the fourth quarter worth approximately $28,000. Geneos Wealth Management Inc. increased its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. Meeder Asset Management Inc. raised its position in shares of Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after acquiring an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its stake in shares of Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after purchasing an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new stake in Neurocrine Biosciences during the first quarter valued at about $33,000. 92.59% of the stock is currently owned by institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported second-quarter revenue of $959 million, up 39% year over year and above analyst estimates of approximately $891 million. Adjusted earnings of $2.85 per share also exceeded consensus estimates. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA net product sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine raised its 2026 INGREZZA sales outlook to $2.825 billion–$2.875 billion. Neurocrine Biosciences Q2 Revenue Rises 39%
• Positive Sentiment: Several analysts raised their price targets after the report, including Stifel, Guggenheim, Needham, Cantor Fitzgerald and Piper Sandler. Targets generally remain above the current trading level, reflecting continued confidence in Neurocrine’s commercial portfolio and pipeline.
• Neutral Sentiment: The Soleno Therapeutics acquisition was completed in May, expanding Neurocrine’s portfolio with VYKAT XR. However, the product contributed only part-quarter sales, leaving investors focused on how quickly the acquisition can add meaningful growth.
• Negative Sentiment: Despite beating quarterly estimates, management did not deliver the broad-based guidance increase or major upside surprise that traders were seeking. The earnings update was therefore viewed as solid but insufficient to support higher expectations, contributing to the selloff.
• Negative Sentiment: Insider trading data shows substantial selling and no open-market purchases by insiders over the past six months. Director Leslie Norwalk’s latest sale involved 1,250 shares and was executed under a pre-arranged Rule 10b5-1 plan, making it a secondary bearish signal rather than clear evidence of a change in business fundamentals. SEC Insider Filing

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.